Oz Biosciences : New Launch Magnetofectamine™ Kit.

Share |

Ideal to transfect primary and hard-to-transfect cells, Magnetofectamine™ is the association of Lipofectamine™ 2000 the most renowned transfection reagent from Life Technologies Corporation (Invitrogen™) with the unique Magnetofection™ based

MARSEILLE (I-Newswire) February 1, 2012 - OZ Biosciences expands its transfection solutions portfolio with the launch of Magnetofectamine™ Kit, the winning combination for optimal transfection efficiency.

OZ Biosciences SAS, specialized in the development of innovative transfection technologies, announces the launch of Magnetofectamine™, a key new product into its comprehensive line of transfection reagents.

Ideal to transfect primary and hard-to-transfect cells, Magnetofectamine™ is the association of Lipofectamine™ 2000 the most renowned transfection reagent from Life Technologies Corporation (Invitrogen™) with the unique Magnetofection™ based reagent CombiMag, from OZ Biosciences™. The alliance of Lipofectamine™ 2000 and CombiMag reagent leads to increased transfection efficiency, minimized toxicity and enhanced gene expression.

"We are pleased to introduce this synergetic association between the leading transfection reagent, Lipofectamine™ 2000, and one of our most popular Magnetofection™ products, CombiMag. This winning combination demonstrates the significant value of our Magnetofection™ technology in the field of transfection" said Olivier Zelphati, CEO of OZ Biosciences.

Magnetofection™ is a simple and highly efficient method to transfect cells in vitro and in vivo. This magnetic assisted transfection is based on the use of magnetic nanoparticles associated to the nucleic acid. In this way, the magnetic force allows a rapid concentration of genetic material onto cells and promotes cellular uptake.

Lipofectamine™ 2000 is the leading transfection reagent on the market for a simple and effective nucleic acid delivery (DNA and siRNA). In the presence of CombiMag reagent, Lipofectamine™ 2000 delivers DNA at higher efficiencies, from +30 to 500%. With Magnetofectamine™, up to 75% transfection efficiencies can be achieved into many primary cells, such as endothelial, chondrocytes, epithelial and human mesenchymal stem cells. Magnetofectamine™ is effective even with low doses of nucleic acids, resulting in minimized cytotoxicity.

OZ Biosciences creates, develops and produces innovative transfection reagents and transduction tools for the scientific community and pharmaceutical industry. As an innovative technology-based company, OZ Biosciences continually provides enabling technologies for the delivery of biomolecules. Located in the Luminy Scientific Park, the heart of important biological research activity in Marseille, France, the company has established a strong position in the field of molecular delivery systems.

For more information please visit www.ozbiosciences.com
Contact: Olivier Zelphati - +33(0)4 86 94 85 16 – contact@ozbiosciences.com
SOURCE: OZ Biosciences

Note to editors
Lipofectamine™ and Invitrogen™ are Trademarks owned by Life Technologies Corporation. Lipofectamine™ 2000 is manufactured by Life Technologies Corporation for OZ Biosciences and provided under license from Life Technologies Corporation

About OZ BIOSCIENCES:
OZ Biosciences creates, develops and produces innovative tools based on drug delivery systems for the worldwide scientific community and pharmaceutical industry. OZ Biosciences focuses on technologies for the delivery of bioactive materials into living organisms.

Company Contact Information
OZ BIOSCIENCES
Olivier ZELPHATI
163 AVENUE DE LUMINY ZONE ENTREPRISE
CASE 922 - MARSEILLE CEDEX 09
13288
Phone : 33 486 84 85 16

Print Release

Share this News Release

Published in:

Nanotechnology

Tags:

Laboratory TRANSFECTION REAGENTS

Published on:

February 1, 2012

Content Disclaimer: If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service company and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter,make sure to check the official company website for accurate release dates as our site displays the date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.

Related Releases

New Capacitive Displacement Sensors Improve Stability And Resolution Performance
Improvements in mechanical design have improved sensor long-term stability and increased resolution to nanotechnology levels of 0.050 nanometers.

Keylogger Hits the Market
iKeyMonitor, iOS Keylogger for iPad, iPhone, iPodTouch and then any other iOS devices, released on February 17, 2012.

HERO BX Adopts Arisdyne’s Oleochemical Cavitation System to Reduce Biodiesel Catalyst Consumption and Lower Monoglycerid
Arisdyne Systems’ Retrofit Equipment Reduces HERO BX Catalyst Consumption by 25%

IPOS3604 VX: When Intelligence Matters! Complete Drive Solution Packed On A Small PCB Space
Based on an innovative design concept, iPOS3604 VX offers high power density (up to 360 W of peak power) on a very compact board (only 21 x 54 mm of PCB space). The drive combines controller, drive and PLC functionality into a single compact unit.

NanoSpire, Inc. Successfully Harnesses Cavitation Zero Point Energy to Produce Dramatic Levels of Fusion & Transmutation In Water
Nanospire, Inc. is announcing successful completion of its investigation of fusion produced by the phenomena of cavitation in water, providing profound implications for the utilities and energy industries.